infectious diseases
Meningococcal Vaccine
Indications for Meningococcal Vaccine
The quadrivalent conjugate meningococcal vaccine is a routine childhood vaccination given to adolescents, preferably at age 11 or 12 years, with a booster dose at age 16 years (seeCDC: Child and Adolescent Immunization Schedule by Age). It is also recommended for younger children who are at high risk of infection. For more information, see also the ACIP'sInfant Meningococcal Vaccination: ACIP Recommendations and Rationale. MenACWYconjugate vaccines are recommended for adults who have conditions that increase risk of meningococcal infection (seeCDC: Adult Immunization Schedule by Age), such as Anatomic or functional Asplenia (including Human Immunodeficiency Virus (HIV) Infection None Persistent Complement deficiencies None Complement inhibitor use (eg,eculizumab,ravulizumab) Work in a microbiology laboratory involving routine exposure to isolates ofNeisseria meningitidis Military recruitment Travel to or residence in endemic areas First year of residence in a college dormitory if students are ≤ 21 years and have not already received a dose on or after their 16th birthday Exposure to an outbreak attributable to a vaccine serogroup If first-year college students aged ≤ 21 years received only 1 dose of vaccine before their 16th birthday, they should be given a booster dose before enrollment. MenACWY is recommended for all adolescents (aged 11 to 18 years), including those with HIV infection. MenACWY is preferred for people aged 11 to 55 years and for those > 55 years who were vaccinated previously with MenACWY and require revaccination or who may require multiple doses of vaccine. Revaccination with MenACWY every 5 years is recommended for adults who were previously vaccinated with MenACWY or MPSV4 and who remain at increased risk of infection (eg, adults with anatomic or functional asplenia, HIV infection, or persistent complement component deficiencies; those who takeeculizumaborravulizumab; microbiologists routinely exposed toN. meningitidis). MenACWYis preferred for at-risk people > 55 years who have not received MenACWY previously and who require only a single dose (eg, travelers). MenB-4CorMenB-FHbpis indicated for people ≥ 10 years with certain high-risk conditions (including people with functional asplenia or complement deficiencies, those who takeeculizumaborravulizumab, microbiologists routinely exposed toN. meningitidis, and those at risk because of a meningococcal disease outbreak attributed to serogroup B). Meningococcal serogroup B vaccines are not routinely recommended by the Centers for Disease Control and Prevention for all adolescents. However, they may be given based on individual clinical decision to anyone aged 16 to 23 years; the preferred age for vaccination is 16 to 18 years. MenB-4C and MenB-FHbp are not interchangeable, so the same product should be used for all doses in series. 